Affinity Asset Advisors, LLC Tango Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$7.51 - $12.88 $1.13 Million - $1.93 Million	-150,000 Reduced 49.95%	150,274 $1.19 Million
Q4 2023 Feb 13, 2024	SELL	$6.52 - $12.01 $324,213 - $597,209	-49,726 Reduced 14.21%	300,274 $2.97 Million
Q3 2023 Nov 14, 2023	BUY	$2.93 - $11.26 $1.03 Million - $3.94 Million	350,000 New	350,000 $3.94 Million
Q3 2022 Nov 14, 2022	BUY	$3.25 - $5.46 $266,441 - $447,621	81,982 New	81,982 $297,000
Q4 2021 Feb 11, 2022	SELL	$9.55 - $14.29 $477,500 - $714,500	-50,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$9.56 - $17.3 $478,000 - $865,000	50,000 New	50,000 $647,000

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $345M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.